Published in J Natl Cancer Inst on December 03, 2003
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (2010) 4.73
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther (2013) 3.11
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol (2010) 2.57
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
A G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J Neurosci (2006) 2.40
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet (2005) 2.39
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res (2007) 2.20
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
CYP2D6 testing in breast cancer: ready for prime time? Oncology (Williston Park) (2009) 2.11
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther (2011) 2.09
Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives. Oncology (Williston Park) (2010) 2.00
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat (2007) 1.68
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Cancer pharmacogenomics: early promise, but concerted effort needed. Science (2013) 1.48
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst (2011) 1.47
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol (2009) 1.46
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst (2008) 1.45
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther (2007) 1.42
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors. J Natl Cancer Inst (2015) 1.41
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat (2007) 1.31
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res (2010) 1.31
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer (2008) 1.22
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids (2007) 1.17
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol (2011) 1.17
Clinically available pharmacogenomics tests. Clin Pharmacol Ther (2009) 1.13
Pharmacogenomics of tamoxifen in a nutshell-and who broke the nutcracker? J Oncol Pract (2005) 1.12
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs (2005) 1.09
Applications of CYP450 testing in the clinical setting. Mol Diagn Ther (2013) 1.08
Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res (2014) 1.07
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer (2010) 1.06
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev (2009) 1.06
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res (2011) 1.05
Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res (2006) 1.02
Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol (2009) 1.01
Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther (2013) 1.01
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
CYP2D6 genotype and tamoxifen response. Breast Cancer Res (2005) 0.99
Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med (2013) 0.99
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res (2011) 0.98
Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat (2011) 0.98
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci (2009) 0.98
Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med (2010) 0.97
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2004) 0.96
Management of hot flashes in women with breast cancer. Curr Oncol (2010) 0.95
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res (2008) 0.95
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat (2013) 0.95
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. Breast Cancer Res Treat (2015) 0.94
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med (2011) 0.94
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med (2013) 0.94
Endocrine resistance in breast cancer - An overview and update. Mol Cell Endocrinol (2015) 0.93
CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenomics Pers Med (2012) 0.93
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol (2009) 0.92
Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat (2012) 0.92
Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. PLoS One (2013) 0.92
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer. Breast Care (Basel) (2008) 0.92
Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS One (2013) 0.91
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol (2011) 0.91
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics (2011) 0.90
Markers of endocrine sensitivity. Breast Cancer Res (2008) 0.90
A decade of letrozole: FACE. Breast Cancer Res Treat (2007) 0.90
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med (2008) 0.89
Management of breast cancer--Part II. BMJ (2008) 0.89
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev (2010) 0.88
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. Int J Mol Epidemiol Genet (2010) 0.88
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers Med (2011) 0.87
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol (2009) 0.87
Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance. Front Pharmacol (2012) 0.87
Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat (2013) 0.86
PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics (2013) 0.85
The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer. Breast Care (Basel) (2012) 0.85
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat (2012) 0.85
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol (2014) 0.85
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int (2015) 0.84
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Curr Signal Transduct Ther (2009) 0.84
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol (2015) 0.84
Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia. J Zhejiang Univ Sci B (2015) 0.84
Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Med (2012) 0.84
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther (2010) 0.83
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol (2012) 4.28
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat (2006) 4.04
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med (2007) 3.36
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol (2005) 2.69
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract (2010) 2.59
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2012) 2.53
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res (2006) 2.46
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol (2012) 2.44
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat (2005) 2.30
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol (2009) 2.23
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol (2010) 2.14
Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol (2012) 2.05
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res (2007) 2.02
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol (2006) 1.88
Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol (2011) 1.85
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84